Nikhil Munshi

Dana-Farber Cancer Institute

Dr. Nikhil Munshi is currently Professor of Medicine in the Department of Medicine at Harvard Medical School, as well as director of Basic and Correlative Science. He is also an attending physician at the VA Boston Healthcare System and Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana Farber Cancer Institute.

Dr. Munshi received his medical degree from the Maharaja Sayjirao University, India, in 1984, then completed his postgraduate training in Internal Medicine at SSG Hospital in Baroda. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and in 1990, began a hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi moved to Harvard in 2001, where he joined the Dana-Farber Cancer Institute. He was the founding member of the International Myeloma Society (IMS), and is currently IMS Vice President. He is also co-chair of the National Steering Committeeon Myeloma (National Cancer Institute), which influences the activities of all US Co-Operative Oncology Groups, as well as a member of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee. Dr Munshi has received a number of awards for recognition of his contributions in cancer research, including a Leukemia Society of America Scholar in Translational Research award, the lifetime achievement award from the Association of VA Hematologist and Oncologist, and in 2013 he received the Waldenström’s Award for his lifetime achievement and contributions to myeloma research.

With over 300 publications in peer-reviewed journals, Dr. Munshi’s interests lie in identifying the molecular mechanisms driving genomic instability in Multiple Myeloma (MM). His research team addresses a wide scope of subjects, including those aimed at improving diagnosis and prognosis, as well as developing novel immunotherapies. He has a strong focus on ‘bench to bedside’ development, with many successful collaborations leading to present day treatments.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter